Coronary artery occlusion adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 13,517 adverse event reports that record the MedDRA preferred term Coronary artery occlusion. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 434 reports in the 12 months to June 2026 and 499 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,049 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 434 (under 0.1%) record this term. Reports for male patients were 56.9% of the reports that record this term and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 107 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Coronary artery occlusion name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetylsalicylic Acid		41
Actos	Peroxisome proliferator receptor alpha agonist	41
Amlodipine	Calcium channel blocker	38
Androgel		57
Angiomax		45
Aspirin	Nonsteroidal anti-inflammatory drug	181
Atacand	Angiotensin 2 receptor blocker	72
Atacand Hct	Thiazide diuretic	59
Atenolol	beta-Adrenergic blocker	119
Atorvastatin		76
Avandamet		74
Avandia		495
Avonex	Interferon beta	373
Betaseron		28
Bextra		107
Bisoprolol	beta-Adrenergic blocker	42
Brilinta	P2Y12 platelet inhibitor	416
Bydureon		29
Byetta	GLP-1 receptor agonist	117
Celebrex	Nonsteroidal anti-inflammatory drug	180
Cisplatin	Platinum-based drug	27
Clopidogrel	P2Y12 platelet inhibitor	95
Clopidogrel bisulfate	P2Y12 platelet inhibitor	33
Cosentyx	Interleukin-17A antagonist	47
Crestor	HMG-CoA reductase inhibitor	373
Dianeal		69
Dianeal Low Calcium		141
Dianeal Low Calcium Peritoneal Dialysis Solution with Dextrose		263
Dianeal Pd4 Solution with 1 5% Dextrose and 2 5 Meq/L Calcium		29
Digoxin	Cardiac glycoside	62
Diovan	Angiotensin 2 receptor blocker	51
Effient	P2Y12 platelet inhibitor	47
Eliquis	Factor Xa inhibitor	50
Enbrel	Tumor necrosis factor blocker	237
Entresto	Angiotensin 2 receptor blocker	185
Extraneal	Osmotic laxative	113
Ezetimibe	Dietary cholesterol absorption inhibitor	35
Forteo	Parathyroid hormone analog	82
Furosemide	Loop diuretic	33
Gilenya	Sphingosine 1-phosphate receptor modulator	28
Heparin		32
Heparin sodium	Anti-coagulant	27
Humalog	Insulin analog	149
Humira		1,682
Humulin 70/30	Insulin	38
Humulin N	Insulin	61
Humulin R	Insulin	42
Ibuprofen	Nonsteroidal anti-inflammatory drug	26
Imbruvica	Kinase inhibitor	88
Lantus	Insulin analog	89
Lipitor	HMG-CoA reductase inhibitor	313
Lisinopril	Angiotensin converting enzyme inhibitor	91
Lyrica		109
Metformin	Biguanide	55
Methotrexate	Folate analog metabolic inhibitor	58
Metoprolol	beta-Adrenergic blocker	70
Metoprolol succinate	beta-Adrenergic blocker	85
Metoprolol tartrate	beta-Adrenergic blocker	39
Neurontin		26
Nexium	Proton pump inhibitor	166
Niaspan		96
Norvasc	Calcium channel blocker	47
Novolog	Insulin analog	40
Ofev	Kinase inhibitor	34
Omeprazole	Proton pump inhibitor	85
Ozempic	GLP-1 receptor agonist	34
Perindopril		41
Plavix	P2Y12 platelet inhibitor	277
Pradaxa	Direct thrombin inhibitor	68
Prednisone	Corticosteroid	100
Prilosec	Proton pump inhibitor	39
Prolia	RANK ligand inhibitor	33
Ramipril	Angiotensin converting enzyme inhibitor	25
Ranolazine		86
Rebif	Interferon beta	218
Remicade	Tumor necrosis factor blocker	71
Reopro		25
Repatha	PCSK9 inhibitor	189
Revlimid	Thalidomide analog	79
Rinvoq	Janus kinase inhibitor	107
Rituxan	CD20-directed cytolytic antibody	26
Rituximab	CD20-directed cytolytic antibody	59
Rosuvastatin	HMG-CoA reductase inhibitor	105
Rosuvastatin calcium	HMG-CoA reductase inhibitor	37
Selozok		70
Seroquel	Atypical antipsychotic	32
Simvastatin	HMG-CoA reductase inhibitor	57
Skyrizi	Interleukin-23 antagonist	216
Symbicort	Corticosteroid	59
Synthroid	l-Thyroxine	50
Tasigna	Kinase inhibitor	91
Tecfidera		53
Testosterone	Androgen	26
Ticagrelor	P2Y12 platelet inhibitor	52
Tiotropium bromide	Anticholinergic	81
Toprol Xl	beta-Adrenergic blocker	33
Tracleer	Endothelin receptor antagonist	25
Tysabri	Integrin receptor antagonist	86
Vedolizumab	Integrin receptor antagonist	58
Venclexta	BCL-2 inhibitor	33
Viagra	Phosphodiesterase 5 inhibitor	60
Victoza	GLP-1 receptor agonist	34
Vioxx		840
Xarelto	Factor Xa inhibitor	32
Xeljanz	Janus kinase inhibitor	56
Xyrem	Central nervous system depressant	33
Zelnorm		25

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 38 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Coronary artery occlusion name, in order of name
Class	Reports with this term
Androgen	52
Angiotensin 2 receptor blocker	387
Angiotensin converting enzyme inhibitor	130
Anticholinergic	97
Atypical antipsychotic	68
Benzodiazepine	55
beta-Adrenergic blocker	421
Biguanide	90
Calcium channel blocker	85
Cardiac glycoside	62
CD20-directed cytolytic antibody	89
Corticosteroid	251
Direct thrombin inhibitor	68
Endothelin receptor antagonist	62
Factor Xa inhibitor	128
Folate analog metabolic inhibitor	69
GLP-1 receptor agonist	231
HMG-CoA reductase inhibitor	922
Insulin	157
Insulin analog	379
Integrin receptor antagonist	148
Interferon beta	601
Interleukin-23 antagonist	218
Janus kinase inhibitor	173
Kinase inhibitor	293
l-Thyroxine	57
Nonsteroidal anti-inflammatory drug	442
Opioid agonist	81
Osmotic laxative	141
P2Y12 platelet inhibitor	939
Parathyroid hormone analog	84
PCSK9 inhibitor	216
Peroxisome proliferator receptor alpha agonist	53
Phosphodiesterase 5 inhibitor	87
Proton pump inhibitor	412
Thalidomide analog	102
Thiazide diuretic	64
Tumor necrosis factor blocker	368

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Coronary artery occlusion, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Coronary artery occlusion
Age	Reports	Share
Under 2	6	under 0.1%
2 to 11	15	0.1%
12 to 17	13	0.1%
18 to 44	637	4.7%
45 to 64	4,414	32.7%
65 to 74	2,747	20.3%
75 and over	1,404	10.4%
Age not given	4,281	31.7%

Sex of the patient in the reports that record Coronary artery occlusion
Sex	Reports	Share
Female	5,373	39.7%
Male	7,692	56.9%
Unknown or not given	452	3.3%

Age and sex are as the report gives them. 70.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Coronary artery occlusion: adverse event reports that record this term. https://reportedreactions.com/reaction/coronary-artery-occlusion/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Coronary artery occlusion mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page